Last updated on

Circulation. Cardiovascular quality and outcomes
Research Hotspot & Journal Scope - PCSK9


Circulation. Cardiovascular quality and outcomes - DOI: 10.1161/CIRCOUTCOMES.118.005404
Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes

Kelly D Myers · Niloofar Farboodi · Mkaya Mwamburi · William Howard · David Staszak · Samuel Gidding · Seth J Baum · Katherine Wilemon · Daniel J Rader ·

Medicine
PDF
Circulation. Cardiovascular quality and outcomes - DOI: 10.1161/CIRCOUTCOMES.119.005910
PCSK9 Inhibitors Prior Authorization.

Khurram Nasir · Suveen Angraal · Salim S Virani ·

Medicine
PDF

In 2003, researchers first showed that gainof-function PCSK9 mutations lead to hypercholesterolaemia in humans.

PCSK9-lowering RNAi contender clears first phase III trial [10.1038/d41573-019-00153-1]


In hepatic cells cpd984 augments ApoB-Lp secretion, increases cellular PCSK9 levels, and reduces LDLR expression indicative of reduced secretion of PCSK9.

Non-Canonical Binding of a Small Molecule to Sortilin Alters Cellular Trafficking of ApoB and PCSK9 in Liver Derived Cells [10.1101/795658]


Changes in the circulating PCSK9 levels have been observed during infection and proinflammatory conditions.

The immune functions of PCSK9: Local and systemic perspectives [10.1002/jcp.28612]


BACKGROUND High PCSK9 concentrations are associated with an increased risk of cardiovascular disease (CVD).

Circulating PCSK9 concentrations are increased in postmenopausal women with the metabolic syndrome. [10.1016/j.cca.2019.04.067]


SummaryIncreasing evidence suggests that PCSK9 inhibitors can produce effective lipid lowering in high risk patients.

The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors [10.1007/s11886-019-1103-2]



Research Hotspot

Circulation. Cardiovascular quality and outcomes

Research Hotspot
Circulation. Cardiovascular quality and outcomes Related Journals

Popular Journals